Estrella immunopharma, inc.ESLAW.US Overview
US StockHealthcare
(No presentation for ESLAW)
ESLAW Overall Performance
ESLAW AI Analysis & Strategy
ESLAW Recent Performance
-
Estrella immunopharma, inc.
0.81%
Avg of Sector
-1.14%
S&P500
ESLAW PowerScanner
ESLAW Key Information
ESLAW Valuation Metrics
ESLAW Earnings Table
ESLAW Profile
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.